Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors.

ABSTRACT: Oncolytic viruses (OVs) have emerged as a very promising anti-cancer therapeutic strategy in the past decades. However, despite their pre-clinical promise, many OV clinical evaluations for cancer therapy have highlighted the continued need for their improved delivery and targeting. Mesenchymal stromal cells (MSCs) have emerged as excellent candidate vehicles for the delivery of OVs due to their tumor-homing properties and low immunogenicity. MSCs can enhance OV delivery by protecting viruses from rapid clearance following administration and also by more efficiently targeting tumor sites, consequently augmenting the therapeutic potential of OVs. MSCs can function as "biological factories," enabling OV amplification within these cells to promote tumor lysis following MSC-OV arrival at the tu

SUBMITTER: Yoon AR 

PROVIDER: S-EPMC8989711 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature